CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
CONCLUSION: Our case series identifies the Sinopharm BBIBP-CorV and the AstraZeneca AZD1222 vaccines as potential triggers for CNS demyelinating diseases. Vaccine administration routines are not affected by these rare and coincidental events. However, these manifestations are not deniable and require serious attention. Further investigations are needed to clarify the actual mechanisms and real associations.PMID:36635139 | PMC:PMC9816077 | DOI:10.1016/j.vaccine.2023.01.003 (Source: Vaccine)
Source: Vaccine - January 12, 2023 Category: Allergy & Immunology Authors: Narges Ebrahimi Mahsa Mazdak Vahid Shaygannejad Omid Mirmosayyeb Source Type: research
Natalizumab
(Source: Reactions Weekly)
Source: Reactions Weekly - January 1, 2023 Category: Drugs & Pharmacology Source Type: research
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
DiscussionAdditional COVID-19 vaccinations can boost the humoral immune response in OCR-pwMS and improve clinical protection against COVID-19. Vaccines effectively protect even OCR-pwMS without a detectable COVID-19 specific humoral immune response, indicating compensatory, e.g., T cell-mediated immunological mechanisms. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - December 23, 2022 Category: Allergy & Immunology Source Type: research
To wait, or too late? modeling the effects of delayed Ofatumumab treatment in relapsing-remitting Multiple Sclerosis
CONCLUSIONS: The DES model provided a means by which the magnitude of benefit associated with earlier ofatumumab initiation could be quantified; fewer relapses and a prolonged time to wheelchair were predicted.PMID:36546701 | DOI:10.1080/13696998.2022.2161746 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 22, 2022 Category: Health Management Authors: Stephen Maxwell Montgomery Luke Green Hajer Karoui Richard Nicholas Jaclyn Loh Source Type: research
OP2 Organizational Impact Model Associated With Switching From Intravenous (IV) to Subcutaneous (SC)
CONTEXT: A new formulation of natalizumab subcutaneous has been recently authorized in highly active relapsing remitting multiple sclerosis (RRMS), offering two routes of administration for individual patient needs (SC and IV). This new presentation might enhance convenience to patients and HCP ’s by saving hospital resources and patient time. (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: H Hadjrabia, D Avot, L Latreche, A Doutriaux Source Type: research
EE650 Cost Effectiveness of Siponimod for Secondary Progressive Multiple Sclerosis in Turkey
The objective of this study is to evaluate the cost effectiveness of siponimod vs natalizumab for SPMS from the Turkish public payer ’s (SGK) perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: M Tatar, T Özbalas, B Saraçoğlu, Ç Ölmez, B Yarci, AC Akdemir, C Yılmaz, S Şen Source Type: research
EE143 Cost-Effectiveness of Ofatumumab Compared with Other Disease-Modifying Therapies for the Treatment of Relapsing Multiple Sclerosis in Greece
Ofatumumab is a high-efficacy disease-modifying therapy (DMT) with a favourable benefit-risk profile recently approved in Greece for the treatment of relapsing multiple sclerosis (RMS). The purpose of this study was to evaluate the cost-effectiveness of ofatumumab vs currently available DMTs (interferon b-1a and -1b, dimethyl fumarate, teriflunomide, glatiramer acetate, ocrelizumab, natalizumab, and fingolimod) for RMS patients from the Greek payer perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: A Petropoulos, P Cooney, M Patidar, K Gudala, S Tiwari, R Brennan, K Kapsogeorgiou, G Cheilas, J Banhazi Source Type: research
EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study
To quantify the economic impact of the adoption of subcutaneous (SC) vs. intravascular (IV) natalizumab administration for the treatment of relapsing remitting multiple sclerosis (RRMS), from the perspectives of Italian patients, multiple sclerosis-centers (MS-centers), and Society. (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: M Filippi, L Grimaldi, A Conte, R Totaro, MR Valente, S Malucchi, F Granella, C Cordioli, V Brescia Morra, D Perini, L Santoni Source Type: research
Risk of melanoma and nonmelanoma skin cancer with immunosuppressants Part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors
In solid organ transplant recipients, skin cancer risk associated with post-transplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used post-transplant, other classes of immunosuppressants also have the potential to raise the risk of nonmelanoma skin cancer (NMSC) or melanoma. In the present manuscript, the evidence for melanoma and NMSC risk associated with methotrexate, cyclophosphamide, biologic cytokine inhibitors including TNF-alpha and interleukin inhibitors, costimulation blockers such as abatacept, integrin inhibitors such as natalizumab, t...
Source: Journal of the American Academy of Dermatology - November 29, 2022 Category: Dermatology Authors: Margaret Ann Kreher, Sailesh Konda, Mary Margaret B. Noland, Maria I. Longo, Rodrigo Valdes-Rodriguez Source Type: research
Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors
In solid organ transplant recipients, skin cancer risk associated with posttransplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used posttransplant, other classes of immunosuppressants also have the potential to raise the risk of nonmelanoma skin cancer (NMSC) or melanoma. In the present manuscript, the evidence for melanoma and NMSC risk associated with methotrexate, cyclophosphamide, biologic cytokine inhibitors including TNF (tumor necrosis factor)-alpha and interleukin inhibitors, costimulation blockers such as abatacept, integrin inhibitors ...
Source: Journal of the American Academy of Dermatology - November 29, 2022 Category: Dermatology Authors: Margaret Ann Kreher, Sailesh Konda, Mary Margaret B. Noland, Maria I. Longo, Rodrigo Valdes-Rodriguez Tags: Continuing medical education Source Type: research
